Montag A & Associates Inc. Reduces Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Montag A & Associates Inc. reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 57.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,212 shares of the medical research company's stock after selling 9,819 shares during the quarter. Montag A & Associates Inc.'s holdings in IQVIA were worth $1,271,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Sowell Financial Services LLC bought a new stake in shares of IQVIA during the 1st quarter valued at $305,000. Mather Group LLC. increased its position in shares of IQVIA by 83.5% during the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after purchasing an additional 350 shares during the last quarter. Park Avenue Securities LLC increased its stake in IQVIA by 40.4% in the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock worth $956,000 after purchasing an additional 1,562 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in IQVIA by 34.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock worth $2,338,000 after purchasing an additional 3,398 shares during the period. Finally, Blair William & Co. IL grew its position in shares of IQVIA by 42.0% in the 4th quarter. Blair William & Co. IL now owns 5,742 shares of the medical research company's stock worth $1,128,000 after buying an additional 1,699 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Up 3.3%

Shares of IQVIA stock traded up $6.41 during trading hours on Thursday, reaching $200.65. 2,558,909 shares of the company were exchanged, compared to its average volume of 2,020,576. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The stock's fifty day moving average is $154.75 and its 200 day moving average is $170.52. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.82 and a current ratio of 0.84. The firm has a market cap of $34.71 billion, a PE ratio of 29.16, a PEG ratio of 2.21 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the prior year, the company posted $2.64 earnings per share. IQVIA's revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. UBS Group boosted their target price on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday. JPMorgan Chase & Co. decreased their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Evercore ISI boosted their price target on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Robert W. Baird boosted their price target on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday. Finally, Citigroup restated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Eight investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and a consensus price target of $227.64.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.